NEVVI Medicare utilization intelligence
Compare this code with others

Jump to the result views

J1602 Injection, golimumab, 1 mg, for intravenous use HCPCS · Treatment
Classification Treatment › Injections and Infusions (nononcologic) › Injection - Tumor Necrosis Factor Blocker (CMS RBCS)
First observed 2014
National scale 40.28M services · est. ▲ 8.5% YoY · 33,757 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 19.86M observed fee-for-service services
CMS descriptor · RBCS classification · Medicare Part B physician/supplier claims, 12-year window · National figures — the MD market is below

See it in full: sestamibi, the nuclear heart-imaging tracer (A9500), in Arizona is open as a live example — every paid panel, on real data.

View the live example →
Data year CY2024 CY2023 CY2022 locked column CY2021 locked column CY2020 locked column
Filter results:
Market summary
Market Brief J1602
A shareable PDF report summarizing this market’s size, trends, and providers.
Preview this Brief →

This market's Overview — its estimated all-Medicare volume, national benchmarks, and what the field charges and is paid — is part of Explore.

See what Medicare pays

An Explore subscription, $249 a seat a year, opens the Overview on every code, group and clinician page, including what the market charges and is paid.

It comes with 25 credits a seat a year for Deep Dives, which open the rest.

Subscribe to Explore →

View the live example →

Included in Explore. Part of a Deep Dive.
Continue from here

Browse Medicare billing by specialty →